Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D02FYE
|
|||
Former ID |
DIB009405
|
|||
Drug Name |
TT-223
|
|||
Synonyms |
E1-INT; GLP1-INT; Islet cell neogenesis therapy, Transition Therapeutics; Islet neogenesis therapy, Transition; Diabetes therapy, Waratah/MGH; EGF-INT, Transition Therapeutics; Glucagon-like peptide + gastrin analog, Transition; INT (diabetes), Waratah/MGH; Epidermal growth factor analog + TT-223 (diabetes), Transition; Islet neogenesis therapy (GLP-1, gastrin), Transition; Glucagon-like peptide + TT-223, (diabetes) Transition
Click to Show/Hide
|
|||
Indication | Type-1 diabetes [ICD-11: 5A10; ICD-9: 250] | Phase 2 | [1] | |
Company |
Waratah Pharmaceuticals Inc
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Gastrin/cholecystokinin type B receptor (CCKBR) | Target Info | Modulator | [2] |
KEGG Pathway | Calcium signaling pathway | |||
Neuroactive ligand-receptor interaction | ||||
Gastric acid secretion | ||||
Panther Pathway | CCKR signaling map ST | |||
Pathwhiz Pathway | Gastric Acid Production | |||
Reactome | Peptide ligand-binding receptors | |||
G alpha (q) signalling events | ||||
Gastrin-CREB signalling pathway via PKC and MAPK | ||||
WikiPathways | GPCRs, Class A Rhodopsin-like | |||
Gastrin-CREB signalling pathway via PKC and MAPK | ||||
Secretion of Hydrochloric Acid in Parietal Cells | ||||
Peptide GPCRs | ||||
GPCR ligand binding | ||||
GPCR downstream signaling | ||||
GPCRs, Other |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT00743002) A Trial of TT223 in Patients With Type 2 Diabetes Who Are Taking Metformin and/or Thiazolidinedione. U.S. National Institutes of Health. | |||
REF 2 | The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans. Int J Obes Relat Metab Disord. 2000 Mar;24(3):288-98. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.